Assessment of rotation thromboelastometry parameters in patients with essential thrombocythemia at diagnosis and after hydroxyurea therapy

Blood Coagulation and Fibrinolysis

Volumn 27, Issue 2, 2016, Pages 205-209

  Treliński, Jacek ^a   Okońska, Marta ^a   Robak, Marta ^a   Chojnowski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

essential thrombocythemia; hydroxyurea; rotation thromboelastometry; thrombosis

Indexed keywords

HYDROXYUREA; NUCLEIC ACID SYNTHESIS INHIBITOR;

ADULT; AGED; ALPHA ANGLE; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLOT FORMATION TIME; CONTROLLED STUDY; ERYTHROCYTE COUNT; HEMATOLOGICAL PARAMETERS; HUMAN; MAXIMUM CLOT FIRMNESS; PRIORITY JOURNAL; ROTATION THROMBOELASTOMETRY PARAMETER; THROMBOCYTE COUNT; THROMBOCYTHEMIA; BLOOD; BLOOD CLOT RETRACTION; CASE CONTROL STUDY; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PATHOLOGY; PROTHROMBIN TIME; ROTATION; THROMBOCYTE; THROMBOCYTHEMIA, ESSENTIAL; THROMBOELASTOGRAPHY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CASE-CONTROL STUDIES; CLOT RETRACTION; ERYTHROCYTE COUNT; FEMALE; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NUCLEIC ACID SYNTHESIS INHIBITORS; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTHROMBIN TIME; ROTATION; THROMBELASTOGRAPHY; THROMBOCYTHEMIA, ESSENTIAL; WHOLE BLOOD COAGULATION TIME;

EID: 84957557213     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000421     Document Type: Article

References (20)

1. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 2000; 79:312-318.
2. Rozman C, Giralt M, Feliu E, Rubio D, Corté s MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67:2758-2763.
3. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128:275-290.
4. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122:2176-2184.
5. Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89:228-232.
6. Trelinski J, Misiewicz M, Robak M, Smolewski P, Chojnowski K. Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thromb Res 2014; 133:667-670.
7. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332:1132-1136.
8. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19:1-10.
9. Piccardoni P, Sideri R, Manarini S, Piccoli A, Martelli N, deGaetano G, et al. Platelet/polymorphonuclear leukocyte adhesion: a new role for SRC kinases in Mac-1 adhesive function triggered by P-selectin. Blood 2001; 98:108-116.
10. Maugeri N, Giordano G, Petrilli MP, Fraticelli V, de Gaetano G, Cerletti C, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug J Thromb Haemost 2006; 4:2593-2598.
11. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of postpolycythemia vera and postessential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22:437-438.
12. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27:81-90.
13. Lang T, Bauters A, Braun SL, Pö tzsch B, von Pape KW, Kolde HJ, et al. Multicentre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005; 16:301-310.
14. Lang T, von Depka M. Possibilities and limitations of thrombelastometry/-graphy. Hamostaseologie 2006; 27:S20-S29.
15. Marchetti M, Falanga A. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol Haemost Thromb 2008; 36:148-159.
16. Nagler M, Kathriner S, Bachmann LM, Wuillemin WA. Impact of changes in haematocrit level and platelet count on thromboelastometry parameters. Thromb Res 2013; 131:249-253.
17. Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, et al. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009; 108:751-758.
18. Iselin BM, Willimann PF, Seifert B, Casutt M, Bombeli T, Zalunardo MP, et al. Isolated reduction of haematocrit does not compromise in vitro blood coagulation. Br J Anaesth 2001; 87:246-249.
19. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120:5128-5133.
20. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015; 90:162-173.